Physician profile
Tamara E Copeland
NPI 1295192805
$1,243.73
in general payments reported to CMS, 2019-2025
6 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $349 · 2022: $306 · 2023: $99.46 · 2024: $380 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521 · Education: $67.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.07 |
| Education | $67.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $921.58 | 2021-2024 | Airsupra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $99.46 | 2024 | Arexvy |
| Genzyme Corporation | $81.37 | 2024 | |
| Verona Pharma, INC. | $74.28 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $35.39 | 2025 | Zemaira |
| Tactile Systems Technology INC | $31.65 | 2024 | Entre Plus, Flexitouch Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.